Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1874 2
1943 2
1944 1
1945 1
1946 1
1947 4
1948 1
1949 5
1950 1
1951 1
1953 2
1954 3
1955 3
1956 3
1957 5
1958 5
1959 4
1960 5
1961 3
1962 5
1963 5
1964 7
1965 16
1966 7
1967 4
1968 8
1969 8
1970 12
1971 7
1972 10
1973 5
1974 10
1975 15
1976 13
1977 13
1978 9
1979 10
1980 9
1981 16
1982 21
1983 15
1984 12
1985 26
1986 26
1987 23
1988 15
1989 21
1990 22
1991 16
1992 31
1993 20
1994 25
1995 30
1996 36
1997 32
1998 39
1999 52
2000 37
2001 50
2002 63
2003 62
2004 87
2005 77
2006 77
2007 95
2008 93
2009 76
2010 88
2011 81
2012 97
2013 85
2014 80
2015 84
2016 86
2017 87
2018 77
2019 99
2020 140
2021 148
2022 152
2023 128
2024 80

Text availability

Article attribute

Article type

Publication date

Search Results

2,724 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean a per[Author] (227 results)?
ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment.
Li PK, Chow KM, Cho Y, Fan S, Figueiredo AE, Harris T, Kanjanabuch T, Kim YL, Madero M, Malyszko J, Mehrotra R, Okpechi IG, Perl J, Piraino B, Runnegar N, Teitelbaum I, Wong JK, Yu X, Johnson DW. Li PK, et al. Among authors: perl j. Perit Dial Int. 2022 Mar;42(2):110-153. doi: 10.1177/08968608221080586. Perit Dial Int. 2022. PMID: 35264029 Free article.
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl AE, Sekeres MA, Dombret H, Amadori S, Wang J, Levis MJ, Schlenk RF; QuANTUM-First Study Group. Erba HP, et al. Among authors: perl ae. Lancet. 2023 May 13;401(10388):1571-1583. doi: 10.1016/S0140-6736(23)00464-6. Epub 2023 Apr 25. Lancet. 2023. PMID: 37116523 Clinical Trial.
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman MS. Pollyea DA, et al. Among authors: perl a. J Natl Compr Canc Netw. 2021 Jan 6;19(1):16-27. doi: 10.6004/jnccn.2021.0002. J Natl Compr Canc Netw. 2021. PMID: 33406488
Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation.
Fernández-Castañeda A, Lu P, Geraghty AC, Song E, Lee MH, Wood J, O'Dea MR, Dutton S, Shamardani K, Nwangwu K, Mancusi R, Yalçın B, Taylor KR, Acosta-Alvarez L, Malacon K, Keough MB, Ni L, Woo PJ, Contreras-Esquivel D, Toland AMS, Gehlhausen JR, Klein J, Takahashi T, Silva J, Israelow B, Lucas C, Mao T, Peña-Hernández MA, Tabachnikova A, Homer RJ, Tabacof L, Tosto-Mancuso J, Breyman E, Kontorovich A, McCarthy D, Quezado M, Vogel H, Hefti MM, Perl DP, Liddelow S, Folkerth R, Putrino D, Nath A, Iwasaki A, Monje M. Fernández-Castañeda A, et al. Among authors: perl dp. Cell. 2022 Jul 7;185(14):2452-2468.e16. doi: 10.1016/j.cell.2022.06.008. Epub 2022 Jun 13. Cell. 2022. PMID: 35768006 Free PMC article.
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K. Pollyea DA, et al. Among authors: perl a. J Natl Compr Canc Netw. 2023 May;21(5):503-513. doi: 10.6004/jnccn.2023.0025. J Natl Compr Canc Netw. 2023. PMID: 37156478
A census of the lung: CellCards from LungMAP.
Sun X, Perl AK, Li R, Bell SM, Sajti E, Kalinichenko VV, Kalin TV, Misra RS, Deshmukh H, Clair G, Kyle J, Crotty Alexander LE, Masso-Silva JA, Kitzmiller JA, Wikenheiser-Brokamp KA, Deutsch G, Guo M, Du Y, Morley MP, Valdez MJ, Yu HV, Jin K, Bardes EE, Zepp JA, Neithamer T, Basil MC, Zacharias WJ, Verheyden J, Young R, Bandyopadhyay G, Lin S, Ansong C, Adkins J, Salomonis N, Aronow BJ, Xu Y, Pryhuber G, Whitsett J, Morrisey EE; NHLBI LungMAP Consortium. Sun X, et al. Among authors: perl ak. Dev Cell. 2022 Jan 10;57(1):112-145.e2. doi: 10.1016/j.devcel.2021.11.007. Epub 2021 Dec 21. Dev Cell. 2022. PMID: 34936882 Free PMC article.
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Daver N, et al. Among authors: perl ae. J Clin Oncol. 2022 Dec 10;40(35):4048-4059. doi: 10.1200/JCO.22.00602. Epub 2022 Jul 18. J Clin Oncol. 2022. PMID: 35849791 Free PMC article. Clinical Trial.
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ. Perl AE, et al. Blood. 2022 Jun 9;139(23):3366-3375. doi: 10.1182/blood.2021011583. Blood. 2022. PMID: 35081255 Free PMC article. Clinical Trial.
The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy.
Bieniek KF, Cairns NJ, Crary JF, Dickson DW, Folkerth RD, Keene CD, Litvan I, Perl DP, Stein TD, Vonsattel JP, Stewart W, Dams-O'Connor K, Gordon WA, Tripodis Y, Alvarez VE, Mez J, Alosco ML, McKee AC; TBI/CTE Research Group. Bieniek KF, et al. Among authors: perl dp. J Neuropathol Exp Neurol. 2021 Feb 22;80(3):210-219. doi: 10.1093/jnen/nlab001. J Neuropathol Exp Neurol. 2021. PMID: 33611507 Free PMC article.
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, Babushok DV, Maillard IP, Carroll MP, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Paralkar VR, Bruno XJ, Hwang WT, Margolis D, Pratz KW. Matthews AH, et al. Among authors: perl ae. Blood Adv. 2022 Jul 12;6(13):3997-4005. doi: 10.1182/bloodadvances.2022007265. Blood Adv. 2022. PMID: 35507945 Free PMC article.
2,724 results